Astellas Pharma Inc. has announced a strategic partnership with Mass General Brigham, aimed at integrating scientific advancements and clinical expertise within the domains of translational medicine and early development.
The collaboration, set to span five years, will concentrate chiefly on oncology, rare diseases, as well as cell and gene therapies. Astellas has revealed that Mass General Brigham's proficiency and capabilities in clinical research, including clinical data and human-derived cell models, will be capitalized upon within the collaboration.
For more health-related news, visit rttnews.com.
